Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 212

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 212
---
 the reporting period end date.

8.    Goodwill and Intangible Assets, Net

GoodwillThe following table sets forth the gross carrying amounts of goodwill (dollars in thousands):Balance as of December 31, 2024$117,019 Goodwill from Sage Acquisition2,061 Balance as of September 30, 2025 (unaudited)$119,080 The increase in goodwill is from the Sage Acquisition. See Note 3, Sage Acquisition, for further discussion. 

25

Intangible Assets, NetThe following table sets forth the gross carrying amounts and related accumulated amortization of intangible assets (dollars in thousands):September 30, 2025December 31, 2024(unaudited)Remaining WeightedAverage Life (Years)Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, NetAcquired in-process research and development$— $— $— $124,000 $— $124,000 Intangible assets subject to amortization:Acquired developed technology and product rights6.6951,811 (328,330)623,481 661,311 (263,399)397,912 Capitalized patent defense costs—43,820 (43,820)— 43,820 (43,820)— Total intangible assets6.6$995,631 $(372,150)$623,481 $829,131 $(307,219)$521,912 Amortization expense for intangible assets was $24.3 million and $64.9 million for the three and nine months ended September 30, 2025, and $19.5 million and $59.7 million for the three and nine months ended September 30, 2024, respectively. In February 2025, the FDA approved ONAPGO and as such, the research and development efforts for the Company's acquired in-process research and development asset is considered complete. As of the FDA approval date, the ONAPGO intangible asset is a definite-life intangible asset subject to amortization and has a useful life of 10 years.In July 2025, the Company acquired ZURZUVAE® (zuranolone), the first and only FDA-approved oral medicine indicated for the treatment of PPD in adults. The ZURZUVAE intangible asset